• Explore /
  • Videos & Slides
  • / Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.

Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.

Abstract Video & Slides

Presenter

Georgina Long

Georgina V. Long, MD, PhD, FRACP

Department of Medical Oncology and Translational Research, Melanoma Institute Australia, The University of Sydney, Mater Hospital and Royal North Shore Hospital

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Videos & Slides Details

Meeting

2018 ASCO Annual Meeting

Session Type

Clinical Science Symposium

Session Title

Compelling Combinations: Raising the Bar With Immunotherapy

Track

Special Sessions

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT02752074

Citation

J Clin Oncol 36, 2018 (suppl; abstr 108)

DOI

10.1200/JCO.2018.36.15_suppl.108

Abstract #

108

Abstract Disclosures

Similar Videos & Slides

Speaker: Ana Baramidze

Speaker: Sajeve Samuel Thomas

Speaker: Nikhil I. Khushalani, MD

Speaker: Dirk Schadendorf, MD